medicalxpress.com
A new blood test, called TriOx, developed by researchers at the University of Oxford, is offering fresh hope for the early detection of multiple cancers. Leveraging the power of machine learning, the test analyzes DNA in the bloodstream to identify subtle cancer signals, potentially enabling earlier and more effective interventions. The study, published in Nature Communications, highlights TriOx's ability to detect six cancer types, including pancreatic and ovarian cancers, with high sensitivity and specificity.
What’s New: A Game-Changing Approach to Liquid Biopsies
Unlike traditional liquid biopsies, which often focus on one or two features of cancer DNA, TriOx combines an advanced DNA analysis technique called TAPS with machine learning to evaluate multiple aspects of DNA. This multimodal approach enhances the test's ability to detect the small fraction of circulating tumor DNA, even in early-stage cancers.
This innovation marks a significant improvement over most current liquid biopsy methods, which are limited in scope. By analyzing multiple features simultaneously, TriOx increases the accuracy and sensitivity of early cancer detection, offering a less invasive and more comprehensive alternative to traditional diagnostic approaches.
Why It Matters: Early Detection Could Revolutionize Cancer Care
The ability to catch cancers earlier, particularly those like pancreatic and ovarian cancer, which often evade detection until advanced stages, could significantly improve survival rates. Early-stage cancers are easier and less costly to treat, making tools like TriOx a potential game changer for both patients and healthcare systems.
Dr. Dimitris Vavoulis, co-lead researcher, emphasized the potential impact.
"Many cancers, such as pancreatic and ovarian, often go unnoticed until they've advanced, when treatment is more difficult and less effective,” Vavoulis said. “Although our approach is still early in development, we envision that a simple blood draw could eventually be all that's needed to screen for multiple cancers, giving patients and doctors a faster, more convenient tool to stay ahead of the disease."
By enabling faster and less invasive screenings, TriOx has the potential to reduce the burden on healthcare systems and improve outcomes for millions of patients worldwide.
Looking Ahead: Expanding and Integrating TriOx
The research team is now working to expand and validate TriOx across more cancer types and larger populations. Their long-term goal is to integrate the test into routine healthcare, making early cancer detection as common as cholesterol or blood sugar screenings.
Professor Anna Schuh, lead researcher and Professor of Molecular Diagnostics at the University of Oxford, explained, "Our new test brings together the best of cutting-edge science and machine learning. It allows us to look at the whole cancer genome, improving reliability. While this test is still early in development, with further work, we believe it has the potential to improve survival rates for millions worldwide, by enabling implementation of routine blood tests to catch cancer earlier, when it's easier to treat."
If TriOx reaches its full potential, it could help redefine cancer screening practices, offering hope for millions worldwide by enabling earlier and more effective treatment.